EQS-News: Prof. Dr. Wiltrud Treffenfeldt leaves Supervisory Board of BRAIN Biotech AG for personal reasons
EQS-News: BRAIN Biotech AG
/ Key word(s): Personnel
Prof. Dr. Wiltrud Treffenfeldt leaves Supervisory Board of BRAIN Biotech AG for personal reasons Zwingenberg, Germany, October 03, 2024 – Professor Dr. Wiltrud Treffenfeldt has informed the Chairman and the other members of the Supervisory Board of the BRAIN Biotech AG that she wishes to resign from her position as an ordinary member of the Supervisory Board of the BRAIN Biotech AG for personal reasons with effect from today. The Supervisory Board has regretfully complied with this request and Prof. Dr. Treffenfeldt will resign from the Supervisory Board as per her wishes as of today, October 03, 2024. Prof. Treffenfeldt has been a member of the Supervisory Board of BRAIN Biotech AG since October 2020. The search for a successor to Prof. Treffenfeldt will be initiated by the Supervisory Board and it is intended to present a suitable candidate to the shareholders for election at the Annual General Meeting in March 2025. The Chairman of the Supervisory Board of BRAIN Biotech AG, Dr. Michael Majerus, expresses his special thanks to Prof. Dr. Treffenfeldt: "Wiltrud Treffenfeldt is a much respected manager and scientist with many years of experience in biotechnology. She has always enriched the discussions in the Supervisory Board with her expertise as well as her personality. I thank her very much for her commitment to BRAIN Biotech AG and wish her – also on behalf of my colleagues on the Supervisory Board and the Executive Board, all the best and every success in her personal and professional future." +++ About BRAIN Biotech BRAIN Biotech AG is a leading provider of integrated solutions and products in the field of industrial biotechnology. The company specializes in enzymes and proteins, microbial production strains and bioprocesses for biotechnological production methods. BRAIN Biotech focuses on the growth markets of nutrition and life sciences as well as on innovative solutions for environment issues. BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. Its business activities are divided into three segments: 1. BioProducts: Production and sale of specialty enzymes and proteins; 2. BioScience: Customized solutions based on enzyme engineering, production strain and bioprocess development, and screening for bioactive compounds; 3. BioIncubator: Pipeline of research-intensive development projects. For production, the Group operates fermentation plants in the UK and other production facilities in continental Europe and the USA. BRAIN Biotech has been listed on the Frankfurt Stock Exchange since February 9, 2016 (ticker: BNN; ISIN DE0005203947 / WKN 520394). The company employs around 310 people and generated revenues of EUR 55.3 million in the fiscal year 2022/23. For more information, please visit www.brain-biotech-group.com
Contact Investor Relations BRAIN Biotech Martina Schuster Contact Media BRAIN Biotech Dr. Stephanie Konle
Disclaimer This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors. BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.
03.10.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | BRAIN Biotech AG |
Darmstädter Straße 34-36 | |
64673 Zwingenberg | |
Germany | |
Phone: | +49 (0) 62 51 / 9331-0 |
Fax: | +49 (0) 62 51 / 9331-11 |
E-mail: | ir@brain-biotech.com |
Internet: | www.brain-biotech.com |
ISIN: | DE0005203947 |
WKN: | 520394 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 2001593 |
End of News | EQS News Service |
|
2001593 03.10.2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
The most important financial data at a glance | ||||||||
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
Sales1 | 27,05 | 38,56 | 38,23 | 38,39 | 45,51 | 55,34 | 65,00 | |
EBITDA1,2 | -6,55 | -2,50 | -3,88 | -2,53 | -1,31 | -0,83 | 3,50 | |
EBITDA-Margin3 | -24,21 | -6,48 | -10,15 | -6,59 | -2,88 | -1,50 | 5,39 | |
EBIT1,4 | -9,57 | -7,20 | -8,23 | -6,55 | -5,65 | -5,48 | 0,00 | |
EBIT-Margin5 | -35,38 | -18,67 | -21,53 | -17,06 | -12,42 | -9,90 | 0,00 | |
Net Profit (Loss)1 | -8,37 | -11,12 | -9,02 | -4,68 | -6,34 | -8,11 | -4,00 | |
Net-Margin6 | -30,94 | -28,84 | -23,59 | -12,19 | -13,93 | -14,66 | -6,15 | |
Cashflow1,7 | -5,42 | -3,38 | -4,77 | -3,10 | -1,49 | -4,22 | -1,50 | |
Earnings per share8 | -0,45 | -0,61 | -0,52 | -0,25 | -0,30 | -0,38 | -0,18 | |
Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Baker Tilly
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
INVESTOR-INFORMATION | ||||||
©boersengefluester.de | ||||||
BRAIN Biotech | ||||||
WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
520394 | DE0005203947 | AG | 75,81 Mio € | 09.02.2016 | Halten | 8FXCPJH6+57 |
PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
34,70 | 0,00 | 0,00 | -7,54 | 3,48 | -17,97 | 1,37 |
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
0,00 | 0,00 | 0,00 | 0,00% |
Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
18.03.2025 | 26.02.2025 | 28.05.2024 | 29.08.2024 | 15.01.2025 |
Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
+17,47% | +32,14% | -5,19% | -1,70% | -61,44% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.